Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

5 treatments under study, led by Rhuepo Injection

Research Leaders

5 sponsors active, led by Coherus Oncology Inc

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
P 2 (1)
P 3 (1)

Trial Status

Unknown1
Completed1
Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT07891377Phase 2Not Yet Recruiting

HEC53856 Tablets for Chemotherapy-induced Anemia in Non-myeloid Malignancies

NCT04466137Phase 3CompletedPrimary

Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy

NCT04662892Unknown

An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca

Showing all 3 trials

Research Network

Common Treatments

  • Rhuepo Injection1
  • Pegfilgrastimcbqv1
  • Ypegrhgcsf1
  • Hec53856 Tablet1
  • Rhgcsfpegrhgcsf1

Active Sponsors

  • Coherus Oncology Inc1
  • Xiamen Amoytop Biotech Co Ltd1
  • Sunshine Lake Pharma Co Ltd1
  • Community Clinical Oncology Research Network Llc1
  • Cancer Institute And Hospital Chinese Academy Of Medical Sciences1

Related Conditions

  • Febrile Neutropenia1
  • Chemotherapyinduced Anemia1

Activity Timeline